Promoter hypermethylation of CCND2 and low CCND2 expression were also associated with a poor prognosis in overall lung and breast cancer, likely because most lung and breast cancer patients with a poor survival have lung adenocarcinoma and TNBC, respectively. The gene discussed is CCND2; the disease is lung adenocarcinoma.